drugset

drugset / Trial / NCT00527033

A Study of YM178 in Patients With Symptomatic Overactive Bladder

NCT00527033 ↗

Phase 2 Completed 842 enrolled Astellas Pharma Inc

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo

Timeline

Start: 2007-09-11
Primary completion: 2008-04-03
Completion: 2008-04-03

Publications

Yamaguchi O, Marui E, Igawa Y, Takeda M, Nishizawa O, Ikeda Y, Ohkawa S. Efficacy and Safety of the Selective beta3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study. Low Urin Tract Symptoms. 2015 May;7(2):84-92. doi: 10.1111/luts.12053. Epub 2014 Mar 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mirabegron	Other / unclassified	25 mg	Oral
Subject	Mirabegron	Other / unclassified	50 mg	Oral
Subject	Mirabegron	Other / unclassified	100 mg	Oral

Indications